ImmunoPrecise Antibodies Ltd. (TSX.V: IPA) (OTCQB: IPATF) Starts Presentation at NobleCon16
ImmunoPrecise (TSX.V: IPA) (OTCQB: IPATF) is an international, full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ progressive single-cell interrogation technology and the DeepDisplay™ custom, OmniAb®-based phage libraries, as well as the Abthena™ bispecific program. ImmunoPrecise discovery and development are conducted in Utrecht and Oss, the Netherlands (U-Protein Express and IPA Europe, respectively), and in Victoria, British Columbia (IPA Canada). The company operates globally to offer a continuum of superior antibody services, transforming the face of therapeutic discovery, by decreasing turnaround time and risk, and promoting clinical success. For more information, visit the company’s…